● neutral
Impact
PhaseApproved (Accelerated Approval)
Time to marketAlready approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
VOCERYQ doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd Updated Nov 2
What to watch
With the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.
Bull case
- VOCERYQ is the first FDA-approved DNA medicine in U.S. history, validating Inovio's plasmid DNA platform and opening a potential pipeline value for other candidates.
- It targets a U.S. prevalent population of at least 25,000 RRP patients who previously had no non-surgical option until Papzimeos in 2025; a second therapy expands the market and gives physicians a differentiated mechanism (DNA vs. adenoviral).
- Analyst consensus is bullish: 5 of 7 analysts rate Buy or Strong Buy, with a mean price target of $3.17 (vs. ~$2.23 pre-market), and HC Wainwright upgraded from Neutral to Buy on Nov 2.
Bear case
- Accelerated approval rests on a single-arm, open-label Phase 1/2 study of just 32 patients; only 27% (7/26) of evaluable patients achieved the complete response of no surgery for 12 months, a modest efficacy signal.
- Continued approval is contingent on a confirmatory study. Inovio must submit a draft protocol by end of 2026 and finalize by mid-2027; failure to verify clinical benefit could lead to withdrawal.
- Inovio faces entrenched competition from Precigen's Papzimeos, approved in August 2025 as the first RRP therapy, which already generated $74.7M in sales and has a head start in the laryngologist prescriber base.